Danaher Corporation's Q3 Numbers Drive Stock Surge

Danaher Corporation reported its third-quarter 2023 results, with net earnings of $1.1 billion and revenues of $6.9 billion, representing a 10.5% decrease year-over-year. The company's non-GAAP adjusted diluted net earnings per common share were $2.02. Danaher's Biotechnology segment performed as expected, while higher respiratory testing revenue offset slightly softer demand in Life Sciences. The company also completed the spin-off of Veralto Corporation and provided its outlook for the fourth quarter and full year 2023, anticipating a decline in non-GAAP base business core revenue.